chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received Moderna COVID booster at 4:30p on Thursday. Around 12:00p on Friday, alerted by watch that resting heart rate was above 120. Was experiencing a resting heart rate as high as 132. Per instructions from familial RN, attempted to rest and bring down heart rate, which would hover around 100-110. As evening progressed, rate came down to around 90. After sleeping through the night, morning rate was fairly normal with resting heart rate around 80. Symptoms may have started as early as 8-9:00p on Thursday; however, due to activity and less severe symptoms, it was not perceived as an issue.
This case was reported by a healthcare professional and described the occurrence of injection site redness in a female subject of unspecified age who was vaccinated with Flulaval (GlaxoSmithKline).  On an unspecified date in 2007 (between 18 September 2007 and 02 October 20007), the subject received unspecified dose of Flulaval (0.5 ml, unknown, left arm).  On the same date as vaccination with Flulaval, the subject experienced injection site redness, injection site pruritus, and swelling injection site.  Medical attention was required at the doctor's office.  The events were resolved on the same day of vaccination/ onset of the adverse events.  The healthcare professional considered the events were probably related to vaccination with Flulaval.  The nurse reported a total of four subjects who experienced similar reactions following administrations of Flulaval between 18 September 2007 and the time of reporting on 02 October 2007 (please see GSK reference numbers A0686373A, A0686379A, and A0686380A).  "Some" of the subjects experienced "swelling at the site of injection to about softball size".  The subjects had previously received influenza vaccinations and had not experienced adverse reactions "other than one patient who may have experienced redness at injection site".
no adverse event; vaccine used which were beyond the 30-Day beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine used which were beyond the 30-Day beyond use date) and NO ADVERSE EVENT (no adverse event) in a 32-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 042J21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Mar-2022, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 09-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine used which were beyond the 30-Day beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (vaccine used which were beyond the 30-Day beyond use date) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (vaccine used which were beyond the 30-Day beyond use date).    Concomitant products were not reported.  It was reported that patient received monovalent dose that was administered beyond 30 day beyond use date. The use by date of lot 042J21A was reported as 17-Feb-2022.  Treatment medications were not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-704416 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jan-2023: Significant Live Follow up received narrative updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704416:Master case
Chills same day noticed at 11:30 pm.  Tylenol taken. Effective.  Next day some fatigue. Returned home from work early.  Napped total of 3 hours: effective. No other concerns.
Within 15 to 30 minutes after receiving 1 st Covid dose, pt began feeling warm/ light-headed. Pt went to healthcare facility where her blood pressure was checked and noted as 152/100, 166/97, 176/102, 176/83. Pt. transported to ER. Pt seen by doctor in ER noted as 155/102,168/92. Pt released from ER. No additional info has been provided.
I developed dermatographia the same day I got the first vaccine. The night after getting the 2nd vaccine I developed a high fever and severe muscle pain. I also had severe shortness of breath. The shortness of breath lasted for the next couple of weeks until I developed nearly constant PVCs. I had/ have bigeminy, trigeminy, and other random PVCs which I was told are multifocal. Two years later my condition has not improved and I am miserable every day.
24-hours after vaccine administration, developed 5 inch diameter area of warmth and erythema.  Appears to be consistent with Arthus-reaction versus injection site reaction unrelated to hypersensitivity.  Lasted ~48-38 hours.
Pt was brought down by the staff c/o general malaise, feeling cold. As pt. sat with me longer she c/o chest discomfort and pain in both her arms and legs. Pt sat with me for 15 min and returned to normal activities. Came down 1 hour later with new c/o chest discomfort worsening and numbness in both hands and fingers and weakness and numbness in her legs. Pt said she feels "awful"
This spontaneous report as received from a medical assistant refers to a 15 month old patient of unknown gender. The concurrent conditions, drug reactions/allergies and medical history of the patient were not reported. On 06-DEC-2016, the patient was vaccinated with a dose of improperly stored MMRII (strength, dose, route of administration, anatomical location, lot number and expiration date were unknown) for prophylaxis, which was stored at 1.1 Celsius degrees (°C) for 27 minutes, 0.7 °C for 19 minutes, 1.1 °C for 36 minutes, 0.7 °C for 29 minutes, 1.3 °C for 17 minutes, 1.1 °C for 20 minutes, 0.9 °C for 26 minutes, 0.7 °C for 31 minutes and 1.2 °C for 24 minutes. There was no previous temperature excursion. Moreover, the temperature excursions were detected by a data logger. No concomitant therapies nor adverse effects were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA007921: US-009507513-1701USA007910: US-009507513-1701USA004148: US-009507513-1701USA003168: US-009507513-1701USA007912: US-009507513-1701USA007922: US-009507513-1701USA007881: US-009507513-1701USA007913: US-009507513-1701USA007882: US-009507513-1701USA004150: US-009507513-1701USA007958: US-009507513-1701USA007906: US-009507513-1701USA007895: US-009507513-1701USA007896: US-009507513-1701USA007923: US-009507513-1701USA004152: US-009507513-1701USA007883: US-009507513-1701USA007897: US-009507513-1701USA007905: US-009507513-1701USA007884: US-009507513-1701USA007925: US-009507513-1701USA007847: US-009507513-1701USA007885: US-009507513-1701USA007908: US-009507513-1701USA007909: US-009507513-1701USA007898: US-009507513-1701USA007914: US-009507513-1701USA007915: US-009507513-1701USA007916: US-009507513-1701USA007848: US-009507513-1701USA007849.
itchy swelling around 3cm, mild erythema in the center around 1.5cm at the injection site on left upper arm (deltoid)
I went through Menopause 5 yrs ago, 1 month after recieving the vaccine, I started my menstral cycle again.  I have multiple cycles so it was not a ONE time thing.
Involuntary jerk movement; This spontaneous case was reported by an other caregiver and describes the occurrence of DYSKINESIA (Involuntary jerk movement) in a 97-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006m2ca) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced DYSKINESIA (Involuntary jerk movement). At the time of the report, DYSKINESIA (Involuntary jerk movement) outcome was unknown.            No concomitant medications were reported. No treatment was reported.   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Follow Up received on 15-APR-2021 Contains Non-significant information - Added daughter's email address On 20-Apr-2021: Follow Up received on 20-APR-2021 Contains Non-Significant Information On 17-May-2021: Follow Up received on 17-MAY-2021 Contains Non-Significant information; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested
Patient was administed expired Covid-19 Moderna Vaccine. Notified Moderna when we were made on 11/17/21. Patient has been called and informed of incident and advised to come in and be given an additional full dose of Covid-19 Moderna Vaccine per the instructions of both Moderna and health office.
The patient is a healthy 12 year old female with no medical history or problems, she received the COVID Pfizer vaccine #1 on Wednesday, May 19th at 4pm and was asymptomatic at that time.  Within  about 5 hours, she began to experience extreme lethargy.  By the following day, May 20th, she experienced profound lethargy that lasted 36hrs.  During this time, she was asleep but arousable with effort, she described general myalgias, moderate left arm pain at injection site, mild headache, no other symptoms.  Her profound lethargy lasted through midday on May 21st, upon which time she was able to keep her eyes open and began to regain her strength.  By the evening of May 21st, she was fully recovered.
Date of onset, baby awoke from nap very irritable, crying, nothing was of comfort. Wouldn't eat. This continued on entire day. Next day, 2/16 baby slept nearly all day, except when I would wake baby to take bath to bring down fever and when I'd wake baby to try and eat/drink. Next day 2/17 baby woke with rash/smooth bumps all over stomach/torso, baby slept nearly all day except when I woke to bathe/attempt to bring down fever and encourage eating/drinking. On 2/18, baby was feeling 'slightly' better, but still very irritated, constantly crying, fever was almost gone. Slept 2 extra hours at nap time and went to bed early. 2/19 baby feeling much better, had interest in playing and eating/drinking. The rash/bumps were starting to fade.
Immediately after patient received her vaccination she said her breathing is changed, she used her Proair. As she was sitting in just 5 minutes and being monitored, she reported tingling inside the roof of her mouth, she was immediately given 50mg of diphenhydramine and famotidine. In about 5 minutes, patient said she felt better and everything has returned to normal. I started to initiate a call to 911 but the patient stopped me and said she would not go that she is all better. Patient was monitored for an hour and her husband who also received the vaccination took her home. The pharmacy followed up on her and she is doing well.
Approximately 30 days after my second dose, I began experiencing bilateral pain in my shoulders,  elbows, behind my knees and, in addition, pain in my buttocks.  The shoulder pain in particular made sleeping difficult; the pain in my buttocks made it difficult for me to sit for more than an hour or so.
Patient reported events of palpitations after receiving the pfizer covid vaccine in July 2023. These palpitations lasted for about a month. they would happen when the patient would walk or exercise. Palpitations started almost immediately after receiving it and lasted just for a month.
Information has been received from a registered nurse concerning an 8-year-old female with a peanut allergy and a history of wheezing who on 26-FEB-1999 was vaccinated in the left thigh with a first dose of varicella virus vaccine live (Oka/Merck) (Lot # 628147/1262H). The patient had cold symptoms at the time of the vaccination. Concomitant therapy included albuterol. On 01-NOV-2006, the patient developed less than 50 vesicles that were itchy over her whole body. On 04-NOV-2006 the patient was seen in the doctor's office, the vesicles were red and some were crusted over (also reported as "2 itchy quarter sized welts with central pimples on her back,"She was afebrile but did  continue to have a stuffy nose and cough. Symptomatic treatment included diphenhydramine (BENADRYL) and an unspecified anti-itch lotion, transmission precautions were also advised. On an unspecified date the patient recovered. No additional information to report. There were no lab diagnostic studies performed. There was no product quality complaint. Additional information is not expected.
Tinnitus, My ears keep ringing for the past 36 hours; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 13May2021 at 09:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0171) via an unspecified route of administration in the left arm on 22Apr2021 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient received any other vaccines within four weeks prior to the vaccination. On 13May2021 at 12:00, the patient experienced tinnitus and her ears kept ringing for the past 36 hours. The patient looked it up, it seemed not many people have this reaction so she wanted to report it. No therapeutic measures were taken as a result of the reported event. The adverse events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of tinnitus, her ears kept ringing was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Extreme weakness. Not enough strength to walk or lift head. Went to emergency room for evaluation. Was given a ketorolac injection to help ease pain. Had a negative COVID-19 test. After roughly 3 hours in the ER, strength had mostly recovered and she was discharged.
Vision was blurred; Tiredness; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (Vision was blurred), FATIGUE (Tiredness), HEADACHE (Headache) and CHILLS (Chills) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced VISION BLURRED (Vision was blurred), FATIGUE (Tiredness), HEADACHE (Headache) and CHILLS (Chills). At the time of the report, VISION BLURRED (Vision was blurred), FATIGUE (Tiredness), HEADACHE (Headache) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment information provided
t101, muscle spasms, gen body aches 24hr p/vax; APAP taken;MD advised advil or aleve & recheck if persists 24hr;
Head felt dizzy about 45 minutes after mist...headache started that night..ears started to swell inside and feel full..throat sore..cough..runny nose..legs/face/hands swelled..took ibuprofen, Tylenol, Afrin, and niacin...called doctor..have apt. at 2:30 today...effects have calmed down...school nurse looked in ears...lots of fluid in both...
fever-fever blister present on mouth 2 days p/shot; 1 wk red, bumps present throughout face;
Patient tested positive for COVID on 2/22/22, admitted to inpatient for 8 days, was released.  Symptoms worsened and returned to the hospital on 3/8/22 and was re-admitted to the hospital.  Comfort care was ultimately discussed and patient passed on 3/16/22.
Beginning about 10 hours after the shot, I experienced, extreme fatigue with body and muscle aches and a low-grade fever.  As the day progressed I developed a terrible, splitting headache, much like a migraine, which I do not normally get.  The fever subsided, but the body aches, fatigue and headache continued all day long. Just as the headache was subsiding, I developed a terrible, painful case of heart burn due most likely to not eating much during the day.   I could not lay flat at all.  The heartburn continued for five hours.  I threw up twice after which I was able to fall asleep.  By the next morning I felt better from the Pfizer shot, but extremely tired from little sleep.  As the day progressed I continued to improve.
Loss all control of arm; This case was reported by a consumer via call center representative and described the occurrence of mobility decreased in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced mobility decreased. On an unknown date, the outcome of the mobility decreased was unknown.   It was unknown if the reporter considered the mobility decreased to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The reporter stated that the patient after vaccination lost all control of arm. This case has been linked with case US2020005633 and US2020AMR006219, reported for same reporter.
Patient is a 99yr old female who got a covid vaccine in the afternoon of 1/10/21 and woke up in the morning of 1/11/21 with altered mental status, weakness, and dysarthria. She was taken from her assisted living facility to the hospital and MRI showed a small stroke in the right medial thalamus. She was also found to have new onset atrial fibrillation. She was treated appropriately for both conditions and discharged to a skilled nursing facility on 1/13/21.
Swollen arm at injection site; Red Arm at injection site; Sore Arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore Arm), PERIPHERAL SWELLING (Swollen arm at injection site) and INJECTION SITE ERYTHEMA (Red Arm at injection site) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore Arm). On 16-Mar-2021, the patient experienced PERIPHERAL SWELLING (Swollen arm at injection site) and INJECTION SITE ERYTHEMA (Red Arm at injection site). At the time of the report, PAIN IN EXTREMITY (Sore Arm), PERIPHERAL SWELLING (Swollen arm at injection site) and INJECTION SITE ERYTHEMA (Red Arm at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were reported No treatment medications were reported
dizziness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 08Apr2021 (Lot number: EW0153) at the age of 52 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Frontal fibrosing alopecia" (unspecified if ongoing); "Known allergies: Singulair" (unspecified if ongoing). Concomitant medication(s) included: VENTOLIN ACCUHALER. Vaccination history included: Bnt162b2 (First dose., Administration time: 14:00., Anatomical location: Left arm., Lot number: ER2613.), administration date: 18Mar2021, when the patient was 52 years old, for Covid-19 immunization, reaction(s): "blistercin L.palm of hand". The following information was reported: DIZZINESS (non-serious) with onset 11Apr2021, outcome "recovering", described as "dizziness". Therapeutic measures were not taken as a result of dizziness.  Additional information:  Treatment was not received for the adverse event. The adverse event of 1st shot was blistercin L.palm of hand. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The most recent COVID-19 vaccine was administered in Hospital. Pfizer have permission to contact patient about this report. Pfizer had not permission to contact the patient's healthcare provider about this report. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19.  No follow-up attempts are needed. No further information is expected.
Patient has had reactions to the last 2 set of shots he's had, so I'd like to document it. He hasn't had any reactions to vaccines until these.  The Hep A shot he had in August made his right arm go numb for about 15 minutes. He complained of pain in his arm for the next 3 days.  The Varicella shot he had last week gave him the first ever visible reaction that he's had to a vaccine. He complained about pain in his right arm following the injection that afternoon. The following morning there was an area of flat redness of 1.5 inches in diameter. By Thurs at 7pm it had grown to a 3 inch by 3 inch area, and was raised. At 10pm, the swelling had increased in the raised area. By Fri morning, the redness remained, but the swelling had gone down. On Sat the area was still red and flat. By Sun afternoon the 3x3 red area is visible, but beginning to fade.
This case was reported by a physician via sales rep and described the occurrence of rash in a male patient who received Hepatitis A vaccine for prophylaxis. On an unknown date, the patient received the 1st dose of Hepatitis A vaccine. On an unknown date, unknown after receiving Hepatitis A vaccine, the patient experienced rash. Hepatitis A vaccine was discontinued. On an unknown date, the outcome of the rash was unknown. It was unknown if the reporter considered the rash to be related to Hepatitis A vaccine. Additional details were provided as follows: The reporting physician was the patient. The age at vaccination was not reported. The patient stated that he experienced a rash after receiving his 1st dose of Hepatitis A so he never received his second dose of Hepatitis A. The reporter did not agree to follow up.
The patient is a pleasant 36 year-old female with no significant medical history, no significant surgical history, no history of    COVID-19. She said she received her second dose of COVID-19  vaccine  on May 9th, 2021 . Three days after her second dose she started noticing fevers all last  week and all this week. She saw her primary care physician, was  noted with hypoxia, decreased O2 saturations on room air and subjective shortness of breath; came into the emergency room. CT angiogram was negative for pulmonary embolism but shows ground glass infiltrates. She is noted with elevated B-natriuretic peptide, elevated troponin-I. Being worked up for myocarditis.
There was not an adverse reaction.  The patient was 17 when they received the Modena vaccine.